Rational Design of N ‐2‐(7‐Chloroquinolin‐4‐ylamino)ethyl Amides Active Against Chloroquine‐Resistant Plasmodium falciparum
Archiv der Pharmazie · 2026
DOI: 10.1002/ardp.70350 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2026. Verfasst von Everton P Silva und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Pesquisa em Bioenergia e Síntese Orgânica (LPBS), Department of Chemistry, Universidade Federal da Paraíba (UFPB), João Pessoa, Brazil. Hauptthemen laut MEDLINE: Plasmodium falciparum, Antimalarials, Drug Design, Chloroquine. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO, FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO.
Abstract (Originalsprache)
Motivated by the antimalarial potential demonstrated by benzamide derivatives of 4‐alkylamino‐7‐chloroquinolines against chloroquine‐resistant Plasmodium falciparum , we designed and synthesized a rational series of N ‐2‐(7‐chloroquinolin‐4‐ylamino)ethyl amides to investigate the effects of electron‐withdrawing and donating substituents on antiplasmodial and cytotoxicity properties, from prediction to in vitro assays. From an initial screening of 22 chloroquine (CQ) analogs, 16 compounds with two distal amino groups in the alkyl linker showed IC 50 values below 1000 nM against the CQ‐sensitive 3D7 strain. Next, their activity against the CQ‐resistant K1 strain, in silico toxicity, predicted using the pkCSM program, and in vitro cytotoxicity on HepG2 cells were evaluated. Benzamides containing electron‐withdrawing chlorine and nitro groups showed the most promising profiles, with IC 50 values against the CQ‐resistant K1 strain (IC 50 K1 , 55–72 nM) and resistance index (RI, 0.7–1.9) values outperforming CQ (IC 50 K1 = 141 nM, RI = 7.1). Although predicted to be hepatotoxic, these compounds were not cytotoxic to HepG2 cells at the tested concentrations, showing CC 50 values above 12,500 nM and selectivity indices greater than 115. Compared with CQ, a 3D qualitative SAR model indicated that increased lipophilicity around the distal benzamide moiety enhances antiplasmodial activity against the K1 strain, contributing to the observed potency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratório de Pesquisa em Bioenergia e Síntese Orgânica (LPBS), Department of Chemistry, Universidade Federal da Paraíba (UFPB), João Pessoa, Brazil.
- Department of Microbiology, Immunology and Parasitology, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
- Institute of Chemistry, Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil.
- Laboratório Multiusuário de Caracterização e Análises (LMCA), Instituto de Pesquisa em Fármacos e Medicamentos (IPeFarM), UFPB, João Pessoa, Brazil.
Förderung
- CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO
- FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO
Zitieren
APA
Silva, E. P., Barbosa, C. S., Aguiar, A. C. C., Oliveira, R. G., Brito, T. A. M., Silva, M. F. R., Souza, H. D. S., Athayde-Filho, P. F., & Fiss, G. F. (2026). Rational Design of N ‐2‐(7‐Chloroquinolin‐4‐ylamino)ethyl Amides Active Against Chloroquine‐Resistant Plasmodium falciparum. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70350
Vancouver
Silva EP, Barbosa CS, Aguiar ACC, Oliveira RG, Brito TAM, Silva MFR, et al. Rational Design of N ‐2‐(7‐Chloroquinolin‐4‐ylamino)ethyl Amides Active Against Chloroquine‐Resistant Plasmodium falciparum. Archiv der Pharmazie. 2026. doi:10.1002/ardp.70350
BibTeX
@article{Silva2026,
author = {Silva, Everton P and Barbosa, Camila S and Aguiar, Anna C C and Oliveira, Ramon G and Brito, Thiago A M and Silva, Marcelo F R and Souza, Helivaldo D S and Athayde-Filho, Petrônio F and Fiss, Gabriela F},
title = {Rational Design of N ‐2‐(7‐Chloroquinolin‐4‐ylamino)ethyl Amides Active Against Chloroquine‐Resistant Plasmodium falciparum},
journal = {Archiv der Pharmazie},
year = {2026},
doi = {10.1002/ardp.70350}
}
EUVIMED